COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,843 Articles (22,553 medRxiv, 8,290 bioRxiv)

Most recent first Previous |  Page 495: Articles 4941-4950  | Next

To test or not to test? A new behavioral epidemiology framework for COVID-19
Sarkar, J.
10.1101/2022.12.22.22283830 — Posted: 2022-12-22
SARS-CoV-2 variant-specific differences in inhibiting the effects of the PKR-activated integrated stress response
Christ, W., Klingstrom, J., Tynell, J.
10.1101/2022.12.21.521388 — Posted: 2022-12-21
Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity
Safra, M., Tamari, Z., Polak, P., Shiber, S., Matan, M., Karameh, H., Helviz, Y., Levy-Barda, A., Yahalom, V., Peretz, A., Ben-Chetrit, E., Brenner, B., Tuller, T., Gal-Tanamy, M., Yaari, G.
10.1101/2022.12.20.521139 — Posted: 2022-12-21
Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
Geyer, C. E., Chen, H.-J., Bye, A. P., Manz, X. D., Guerra, D., Caniels, T. G., Bijl, T. P. L., Griffith, G. R., Hoepel, W., de Taeye, S. W., Veth, J., Vlaar, A. P. J., Amsterdam UMC COVID-19 Biobank, , Vidarsson, G., Bogaard, H. J., Aman, J., Gibbins, J. M., van Gils, M. J., Winther, M. P. J., den Dunnen, J.
10.1101/2022.12.20.521247 — Posted: 2022-12-21
Structure adaptation in Omicron SARS-CoV-2/hACE2:Biophysical origins of evolutionary driving forces
Hsiao, Y.-W., Taddese, T., Jimenez-Serratos, G., Bray, D. J., Crain, J.
10.1101/2022.12.20.521221 — Posted: 2022-12-21
Mechanism of LLPS of SARS-CoV-2 N protein
Song, J.
10.1101/2022.12.21.521431 — Posted: 2022-12-21
Stratification of hypertensive COVID-19 patients by quantitative NMR spectroscopy of serum metabolites, lipoproteins and inflammation markers
Kazenwadel, J., Berezhnoy, G., Cannet, C., Schaefer, H., Geisler, T., Rohlfing, A.-K., Gawaz, M., Merle, U., Trautwein, C.
10.1101/2022.12.20.22283729 — Posted: 2022-12-21
An approach to rapid distributed manufacturing of broad spectrum anti-viral griffithsin using cell-free systems to mitigate pandemics
Borhani, S. G., Levine, M. Z., Krumpe, L. H., Wilson, J., Hendrich, C., O'Keefe, B., Lo, D., Sittampalam, G., Godfrey, A., Lunsford, R. D., Mangalampalli, V., Tao, D., LeClair, C. A., Thole, A., Frey, D., Swartz, J. R., Rao, G.
10.1101/2022.12.19.521044 — Posted: 2022-12-20
Adenoviral-Based Vaccine Elicits Robust Systemic and Mucosal Cross-Reactive Responses in African Green Monkeys and Reduces Shedding after SARS-CoV-2 Challenge
Tedjakusuma, S. N., Lester, C. A., Neuhaus, E. D., Dora, E. G., Tucker, S. N., Flitter, B. A.
10.1101/2022.12.19.521127 — Posted: 2022-12-20
An oral vaccine for SARS-CoV-2 RBD mRNA-bovine milk-derived exosomes induces a neutralizing antibody response in vivo
Zhang, Q., Wang, M., Han, C., Wen, Z., Meng, X., Qi, D., Wang, N., Du, H., Wang, J., Lu, L., Ge, X.
10.1101/2022.12.19.517879 — Posted: 2022-12-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).